Previous studies have reported that combination of anti‐ANXA3 (Tong et al, 2018) or Cdk5 inhibition (Ardelt et al, 2019) with sorafenib acts as novel strategies to improve sorafenib response in HCC treatment. Here, ANXA3 is linked to hepatocellular carcinoma.